Lysostaphin variants and methods of use thereof
AssigneeBiomEdit, Inc.
InventorYong-Fu LI
Life of this patent
Estimating the term…
Abstract
The present disclosure provides lysostaphin variants comprising one or more amino acid mutations in the lysostaphin sequence as well as formulations and methods of using the lysostaphin variants which exhibit desirable properties and provide benefits for the treatment of infections in animals.
Claims35
A lysostaphin variant comprising a lysostaphin sequence of SEQ ID NO:5 and comprising at least one amino acid mutation selected from the group consisting of G25P, G25S, G25T, N27E, N27T, N27D, N27V, N27S, N27A, G29S, G29T, G56S, G62S, T126N, G143S, and S233A.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising the lysostaphin sequence of SEQ ID NO:5 and comprising at least one amino acid mutation selected from the group consisting of G25 P, G25S, G25T, N27E, N27T, N27D, N27V, N27S, N27A, G29S, G29T, G56S, G62S, T126N, G143S, and S233A.
A method of treating an infection in an animal, said method comprising the steps of administering a lysostaphin variant or a pharmaceutical composition thereof comprising a lysostaphin sequence of SEQ ID NO:5 and comprising at least one amino acid mutation selected from the group consisting of G25P, G255, G25T, N27E N27T N27D, N27V, N27S, N27A G29S, G29T, G565 G62S T126N G143S and S233A, wherein the lysostaphin variant or pharmaceutical composition thereof reduces one or more symptoms associated with the infection in the animal.
(canceled)
A recombinant nucleic acid vector comprising a transcription promoter, a nucleic acid sequence encoding a lysostaphin polypeptide sequence of SEQ ID NO:
- 5 and comprising at least one amino acid mutation selected from the group consisting of G25P, G25S, G25T, N27E, N27T, N27D, N27V, N27S, N27A, G29S, G29T, G56S, G62S, T126N, G143S, and S233A, and a transcriptional terminator.
A method of producing a lysostaphin variant comprising a lysostaphin sequence of SEQ LD NO:4 and comprising at least one amino acid mutation selected from the group consisting of G25P, G25S, G25T, N27E, N27T, N27D, N27V, N27S, N27A, G129S, G29T, G56S, G62S, and T126N, said method comprising inducing expression of the lysostaphin polypeptide from the recombinant nucleic acid vector a transcription promoter, a nucleic acid sequence encoding a lysostaphin polypeptide sequence of SE ID NO:5 and comprising at least one amino acid mutation selected from the group consisting of G25P, G25S, G25T N27E N27T, N27D N27V, N27S, N27A, G29S, G29T, G56S, G62S, T126N, G143S, and S233A, and a transcriptional terminator in a cell.
(canceled)
Dependencies are inferred from the claim text.